Almirall Sues Amneal to Block Copies of Aczone Acne Treatment

Almirall says Amneal’s proposed generic version of Aczone Gel 7.5%, used to treat acne vulgaris, infringes an Almirall patent.

• Almirall is seeking a court order blocking copies until the patent has expired, and to collect cash compensation if copies are made before then, according to complaint filed Tuesday in federal court in Wilmington, Delaware
• Patent expires in November 2033, complaint says
• Aczone had sales of 24 million euros ($27 million) in 2018, 3.2% of revenue: data compiled by Bloomberg
• Almirall and Taro in March settled another case, also in Delaware, over the same patent
• CASE: Almirall LLC v. Amneal ...